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Abstract
Aims/hypothesis Our aim was to assess regression of albuminuria and its clinical consequences in type 1 diabetes.
Methods The analysis included 3642 participants from the Finnish Diabetic Nephropathy (FinnDiane) Study with a 24 h urine
sample and a history of albuminuria available at baseline. A total of 2729 individuals had normal AER, 438 a history of
microalbuminuria and 475 a history of macroalbuminuria. Regression was defined as a change from a higher category of
albuminuria pre-baseline to a lower category in two out of the three most recent urine samples at baseline. The impact of
regression on cardiovascular events (myocardial infarction, stroke, coronary procedure) and mortality was analysed over a
follow-up of 14.0 years (interquartile range 11.9–15.9).
Results In total, 102 (23.3%) individuals with prior microalbuminuria and 111 (23.4%) with prior macroalbuminuria had
regressed at baseline. For individuals with normal AER as a reference, the age-adjusted HRs (95% CI) for cardiovascular events
were 1.42 (0.75, 2.68) in individuals with regression from microalbuminuria, 2.62 (1.95, 3.54) in individuals with sustained
microalbuminuria, 3.15 (2.02, 4.92) in individuals with regression from macroalbuminuria and 5.49 (4.31, 7.00) in individuals
with sustained macroalbuminuria. Furthermore, for all-cause and cardiovascular mortality rates, HRs in regressed individuals
were comparable with those with sustained renal status at the achieved level (i.e. those who did not regress but remained at the
most advanced level of albuminuria noted pre-baseline).
Conclusions/interpretation Progression of diabetic nephropathy confers an increased risk for cardiovascular disease and prema-
ture death. Notably, regression reduces the risk to the same level as for those who did not progress.
Keywords Albumin excretion rate . Albuminuria . Cardiovascular disease . Diabetic nephropathy .Mortality . Type 1 diabetes
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Regression of albuminuria and its association with incident
cardiovascular outcomes andmortality in type 1 diabetes: the FinnDiane
Study
Introduction
Despite vast advances in therapy, diabetic nephropathy re-
mains a leading cause of illness and death in every third indi-
vidual with type 1 diabetes. Early identification of individuals
with increased risk of renal complications is therefore crucial.
Microalbuminuria, present at the first stages of diabetic ne-
phropathy, has served this purpose since the 1980s, when it
emerged with an 80% progression rate to overt nephropathy
[1–3]. However, this view has since been challenged by a
number of studies suggesting much lower progression rates.
Some studies even indicate that microalbuminuria regresses to
normoalbuminuria more frequently than it persists or pro-
gresses [4–6]. Yet, in spite of the discrepancy regarding its
prognostic value, no other clinical marker has so far been
measured as broadly as AER in order to assess renal risk in
individuals with diabetes.
In addition to predicting renal outcomes, albuminuria is
also a strong predictor of cardiovascular disease [7–9].
Individuals with type 1 diabetes and nephropathy carry a
tenfold greater risk of cardiovascular events compared
with individuals with no nephropathy [10]. Small eleva-
tions of the AER translate into an increased cardiovascu-
lar risk [11]. Notably, a positive correlation between a
reduction in albuminuria and cardiovascular events has
been shown regardless of the baseline AER [8].
Albuminuria is further associated with premature death
[12–15], which in individuals with type 1 diabetes is
mainly due to cardiovascular factors [15]. Similarly, mor-
tality rate has been reported to increase concomitantly
with increasing levels of AER [14].
Data on the clinical consequences of regression of albu-
minuria in type 1 diabetes are scarce. Therefore, the present
study was designed to assess regression of albuminuria and to
study the impact of regression on cardiovascular risk and all-
cause and cardiovascular mortality rates in a well-
characterised cohort of individuals with type 1 diabetes.
Methods
This study is part of the Finnish Diabetic Nephropathy
(FinnDiane) Study, which is a nationwide, multicentre study
designed to reveal the risk factors and mechanisms of diabetic
complications in individuals with type 1 diabetes, with a spe-
cific focus on nephropathy. A detailed description of the study
setting has been reported previously [16]. In brief, the study
includes adults (≥18 years) from over 80 participating centres
(see electronic supplementary material [ESM] for a list of the
FinnDiane Study centres). Baseline visits for the participants
included in the current analyses were completed between
1997 and 2011. At baseline, all participants underwent a thor-
ough clinical examination and completed standardised ques-
tionnaires regarding health and medical history in collabora-
tion with their attending physician. Early morning blood sam-
ples were collected for the analysis of HbA1c, lipids and cre-
atinine. eGFR was calculated with the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula
[17]. BP was measured twice in the sitting position after a
10min rest, and the mean values for both systolic and diastolic
BP were used in the analyses. Antihypertensive medication
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Of the original FinnDiane Study dataset comprising 5272
participants (by December 2016), 3642 met the entrance
criteria for the present study. All individuals with end-stage
renal disease (ESRD) were excluded, and to ensure correct
diagnosis of type 1 diabetes, age at onset ≤40 years and tran-
sition to permanent insulin treatment within 1 year of diagno-
sis were required. The research plan was approved by the local
ethics committees and the study was performed according to
the Declaration of Helsinki. All participants provided written
informed consent.
Measurements of urinary AER and definition of regression
Microalbuminuria was defined as a urinary AER of 30–
300 mg/24 h or 20–200 μg/min, or a urinary albumin to cre-
atinine ratio (ACR) of 2.5–25 mg/mmol for men and 3.5–
35 mg/mmol for women. Normal AER was defined as the
range below the lower reference value for microalbuminuria
and the range above the upper reference limit for
macroalbuminuria. ESRD was defined as ongoing renal re-
placement therapy (dialysis or renal transplantation).
Figure 1 illustrates a schematic algorithm of the characterisa-
tion of the main outcome of the study. At baseline, a centrally
measured 24 h urine sample, as well as the prior history of
albuminuria from medical records was available. The records
included either AER measurements made from 24 h urine
samples or from timed overnight urine samples, or ACR mea-
surements, depending on sample collection method at each
centre. The conventionally used clinical classification of albu-
minuria, based on a minimum of two out of three consecutive
urine samples, was accomplished for each participant pre-
baseline (i.e. prior to the first FinnDiane Study visit). Every
urine albumin measurement preceding the visit was screened
and the most advanced stage of albuminuria was noted.
Potentially confounding factors were carefully scrutinised by
FinnDiane Study physicians and no urine samples collected
during fever, urinary tract infections, menstruation, pregnancy
or after heavy exercise were taken into account. In addition,
we performed a revised classification, based on the three most
recent collections at baseline, independently of the initial clas-
sification of albuminuria. It is of note that no generally accept-
ed definition of regression of albuminuria exists. In this study
we defined regression as a reversion from a higher pre-
baseline status to a lower category of albuminuria measured
at baseline (i.e. from microalbuminuria to normal AER, or
from macro to microalbuminuria or normal AER).
Follow-up data and ascertainment of outcomes The
FinnDiane Study is an ongoing study and regular follow-up
visits have been conducted since 2004. In addition to data
collected during these follow-up visits, we reviewed all data
available from the medical files and the laboratory databases
in order to catch comprehensive follow-up information. Data
collected until 31 December 2014 were used in this study and
the median follow-up time was 14.0 years (interquartile range
[IQR] 11.9–15.9). Follow-up data on cardiovascular events
were obtained from the National Care Register of Health
Care, which is the national hospital discharge register in
Finland, and Statistics Finland. The combined cardiovascular
outcome included first acute myocardial infarction (ICD-8/9:
410–412, ICD-10: I21–I23; www.who.int/classifications/icd/
en/), cerebrovascular accident (ICD-8/9: 430–434, ICD-10:
I60–I64) and coronary procedure (bypass grafting surgery or
angioplasty based on the Nordic Classifications of Surgical
Procedures). In the analyses concerning cardiovascular
disease, only the 3449 individuals without a verified
cardiovascular event at baseline were included. The
individuals included were younger, had a shorter duration of
diabetes, lower levels of BP and were more often women than
those who were excluded (data not shown). The data on
deaths were obtained from Statistics Finland. Mortality rate
analyses were performed for both all-cause and cardiovascular
mortality rates. The cause of death was classified as cardio-
vascular if the immediate, underlying or intermediate cause of
death (or several of these) was recorded as disease of the
circulatory system.
Statistical analysesDescriptive clinical characteristics are pre-
sented as means ± SD (continuous variables with symmetric
distributions), median with IQR (continuous variables with
skewed distributions) or percentages (categorical variables).
Between-group differences in continuous variables were
analysed with ANOVA, Student’s t test or Mann–Whitney U
test as appropriate. Between-group differences in categorical
variables were tested with Pearson’s χ2 test.
Cumulative incidence curves for cardiovascular events and
mortality rates (all-cause and cardiovascular) were created
with the Kaplan–Meier estimator. The association between
regression of albuminuria and the cardiovascular outcome
and mortality rate was estimated using Cox proportional haz-
ards modelling. The analyses are age-adjusted and presented
a
a
Conventional classification of albuminuria
Revised classification of albuminuria




Fig. 1 A schematic algorithm illustrating the definition of the main study
outcome, regression of albuminuria. a denotes the central urine sample at
baseline. Black arrows, microalbuminuria; red arrows, macroalbuminuria
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as HRs with 95%CIs. The five groups of albuminuria status at
baseline (individuals with normal AER, individuals that
regressed from microalbuminuria, individuals with sustained
microalbuminuria, individuals that regressed from
macroalbuminuria and individuals with sustained
macroalbuminuria) were pairwise compared and all p values
reported from these analyses were adjusted for age.
Cumulative cardiovascular mortality rates incorporating death
from other causes as a competing risk was determined using
the Fine–Gray method [18].
To further estimate the association between regression of
albuminuria and cardiovascular disease, Cox regression
analyses were performed comparing individuals with
regression of albuminuria vs individuals with sustained renal
status with respect to incident cardiovascular events during
follow-up. Individuals with a history of microalbuminuria
(regressed and sustained) and individuals with a history of
macroalbuminuria (regressed and sustained) were analysed
separately, and in addition, a pooled analysis with all individ-
uals combined is presented (HR [95% CI]), as no interaction
between regression and history of microalbuminuria/
macroalbuminuria was observed. Selection of covariates to
the multivariable models was based on univariate associations
at the level of p < 0.05. First, regression of albuminuria (yes/
no) was adjusted for the static confounders sex, age and age at
onset of diabetes (model 2). The second multivariable model
(model 3) also included dynamic confounders. In addition to
HbA1c, waist-to-hip ratio and eGFR, systolic BP was selected
to represent the BP level (diastolic BP excluded to avoid
multicollinearity) and non-HDL-cholesterol was selected
from the lipid profile because of its well-established role in
predicting cardiovascular events.
All analyses were conducted using IBM SPSS Statistics for
Windows, version 22.0 (IBM, Armonk, NY, USA) and R
open source software version 3.2.2 (http://www.r-project.
org). A two-sided p value <0.05 was considered to be statisti-
cally significant.
Results
Of the 3642 participants in this study, 2729 (74.9%) had normal
AER at baseline. A total of 438 individuals (12.0%) were ini-
tially classified as microalbuminuric and 475 (13.0%) as
macroalbuminuric. Of the individuals with initial
microalbuminuria, 102 (23.3%) were reclassified as
normoalbuminuric based on the three most recent urinary
AER measurements at the baseline visit. Similarly, 111
(23.4%) of the 475 individuals with initial macroalbuminuria
had regressed. Twenty individuals had regressed from
macroalbuminuria to normal AER at baseline, but because of
low power, these individuals were pooled with those with re-
gression from macro to microalbuminuria in all analyses.
Table 1 presents the clinical characteristics of all participants
stratified into five groups by albuminuria status at baseline.
The individuals who had regressed from microalbuminuria to
normal AER had lower HbA1c, total cholesterol and LDL-
cholesterol at baseline compared with the individuals with no
change in microalbuminuria. Compared with macroalbuminuric
individuals with no change, the individuals with regression from
macroalbuminuria were more often women and had more
favourable BP, HbA1c, eGFR and lipid profiles.
The impact of regression of albuminuria on incident cardio-
vascular disease Of the 3449 individuals without previous
myocardial infarction, coronary procedure or stroke, 365
(10.6%) experienced at least one confirmed cardiovascular
event during the prospective phase of the study. The
Kaplan–Meier curves shown in Fig. 2 illustrate the cumulative
incidences of first cardiovascular event stratified by albumin-
uria status at baseline. The 15 year cumulative incidences
were 8.0% (6.7, 9.3) for normal AER, 13.2% (6.1, 19.7) for
microalbuminuria regression, 21.5% (17.4, 25.4) for sustained
microalbuminuria, 28.7% (20.3, 36.2) for macroalbuminuria
regression and 40.1% (36.3, 43.6) for sustained
macroalbuminuria. Age-adjusted HRs for incident cardiovas-
cular events with individuals with normal AER as a reference
are presented in Table 2. After adjustment, no difference was
observed between individuals with normal AER and regres-
sion from microalbuminuria and, similarly, between sustained
microalbuminuria and regression from macroalbuminuria.
However, individuals with regressed macroalbuminuria dif-
fered from those with sustained macroalbuminuria (p =
0.018), and a borderline significance was also noted between
individuals with regressed microalbuminuria and sustained
microalbuminuria (p = 0.067).
To further assess the association between regression of al-
buminuria and cardiovascular events, individuals with regres-
sion were compared with those with sustained renal status
using Cox proportional hazards models. These results are pre-
sented in Table 3 for individuals with a history of
microalbuminuria and macroalbuminuria separately, and ad-
ditionally, for all individuals combined. After adjustment for
the static confounders sex, age and age at onset of diabetes
(model 2), a significant association between reduction of al-
buminuria and reduction of cardiovascular events remained
for all groups. However, after the final adjustment for dynamic
confounders, no independent association between regression
and the adverse outcome was observed.
The impact of regression of albuminuria on mortality rate In
total, 370 individuals (10.2%) died by the end of 2014. All-
cause mortality rate, stratified by albuminuria status at base-
line, is presented in Fig. 3. The obtained 15 year cumulative
incidences for all-cause mortality rate were 6.1% (5.2, 7.0) for
normal AER, 8.8% (3.3, 14.0) for microalbuminuria
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r e g r e s s i o n , 19 . 2% (15 . 5 , 22 . 8 ) f o r s u s t a i n ed
microalbuminuria, 25.1% (18.5, 31.2) for macroalbuminuria
regression and 38.1% (34.9, 41.2) for sustained
macroalbuminuria. The age-adjusted HRs for all-cause mor-
tality rate are presented in Table 2. As with cardiovascular
events, the individuals who regressed showed a lower risk of
death compared with those with no improvement in their renal
status (p = 0.039 for regression from microalbuminuria vs
sustained microalbuminuria and p = 0.003 for regression from
macroalbuminuria vs sustained macroalbuminuria). However,
when comparing the individuals with normal AER with the
individuals whose microalbuminuria regressed, the difference
was non-significant. Not unexpectedly, this was also the case
for sustained microalbuminuria vs regression from
macroalbuminuria.
A total of 59% (n = 199) of the causes of death were car-
diovascular, and the majority of these were ischaemic heart
diseases (I20–I25). The 15 year cumulative incidences for
cardiovascular mortality rate are illustrated in Fig. 4 and were
calculated to be 2.9% (2.1, 3.7) for normoalbuminuria, 4.7%
(0.1, 9.0) for microalbuminuria regression, 9.9% (6.8, 12.9)
for sustained microalbuminuria, 14.3% (8.0, 20.1) for
macroalbuminuria regression and 24.1% (20.6, 27.4) for
sustained macroalbuminuria. Age-adjusted HRs for cardio-
vascular mortality rate are presented in Table 2. Among the
individuals with a history of macroalbuminuria, an association
between regression of albuminuria and lower cardiovascular
mortality rate was observed in the same manner as for cardio-
vascular events and all-cause mortality rate (p = 0.004).
Individuals with normal AER vs those with microalbuminuria
regression and individuals with sustained microalbuminuria
vs individuals with macroalbuminuria regression were no dif-
ferent with regard to the outcome. Similarly, the difference
between regressed and sustained microalbuminuria regarding
this outcome was non-significant; however, only four individ-
uals with microalbuminuria regression had died from cardio-
vascular causes during follow-up. The finding remained with
the Fine–Gray competing-risk analysis, incorporating death
from other causes as a competing risk, as the difference be-
tween individuals with and without regression among those
with a history of macroalbuminuria reached statistical signif-
icance (p = 0.005) but the other comparisons did not (ESM
Fig. 1).
Discussion
In this multicentre study of 3642 Finnish individuals with type
1 diabetes, we compared the revised classification of albumin-
uria, based on the three most recent urine samples at baseline,
Table 1 Clinical characteristics at baseline stratified by status of albuminuria
Variable Normal AER Microalbuminuria Macroalbuminuria
Regression No change p value Regression No change p value
n 2729 102 336 111 364
Men (%) 48 54 61 0.183 46 63 <0.001
Age (years) 36.4 ± 11.9 38.1 ± 12.0 39.5 ± 12.1 0.310 41.9 ± 10.2 41.0 ± 10.1 0.448
Age at onset of diabetes (years) 17.8 ± 9.5 12.9 ± 8.4 13.3 ± 9.0 0.665 12.5 ± 8.8 12.3 ± 7.3 0.804
Duration of diabetes (years) 18.6 ± 12.0 25.3 ± 11.2 26.2 ± 10.8 0.451 29.3 ± 7.7 28.7 ± 8.4 0.485
BMI (kg/m2) 24.9 ± 3.4 25.5 ± 3.1 25.9 ± 3.6 0.336 26.4 ± 4.2 25.8 ± 4.1 0.233
Systolic BP (mmHg) 130 ± 16 134 ± 16 136 ± 17 0.318 138 ± 18 146 ± 19 <0.001
Diastolic BP (mmHg) 78 ± 9 79 ± 9 80 ± 10 0.174 79 ± 10 84 ± 10 <0.001
Use of RAAS inhibitorsa (%) 11 53 65 0.026 88 84 0.467
History of smoking (%) 39 49 52 0.802 53 59 0.096
HbA1c (mmol/mol) 66.5 ± 15.3 69.2 ± 14.4 72.7 ± 15.5 0.041 71.4 ± 15.3 75.8 ± 16.3 0.012
HbA1c (%) 8.2 ± 1.4 8.5 ± 1.3 8.8 ± 1.4 0.041 8.7 ± 1.4 9.1 ± 1.5 0.012
Serum creatinine (μmol/l) 79 (69–89) 88 (79–100) 88 (77–100) 0.951 107 (87–145) 132 (100–192) <0.001
eGFR (ml min−1 [1.73 m]−2) 97 (82–111) 86 (72–102) 88 (71–101) 0.773 65 (41–78) 54 (33–75) 0.003
Total cholesterol (mmol/l) 4.78 ± 0.88 4.77 ± 0.86 5.06 ± 0.89 0.004 5.09 ± 0.93 5.48 ± 1.11 <0.001
HDL-cholesterol (mmol/l) 1.39 ± 0.38 1.28 ± 0.38 1.32 ± 0.39 0.393 1.21 ± 0.34 1.21 ± 0.40 0.972
LDL-cholesterol (mmol/l) 2.93 ± 0.80 2.96 ± 0.80 3.16 ± 0.83 0.039 3.26 ± 0.86 3.48 ± 0.88 0.026
Triacylglycerol (mmol/l) 0.93 (0.72–1.28) 1.08 (0.75–1.49) 1.06 (0.84–1.58) 0.267 1.27 (0.90–1.72) 1.46 (1.06–2.10) 0.003
Data are means ± SD, median (IQR) or percentages
p values denote differences between regression and no change groups
a ACE inhibitor and/or angiotensin II receptor antagonist
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with the most advanced stage of albuminuria noted pre-base-
line. Regression was defined as a reversion from a higher to a
lower category of albuminuria. Consequently, 23% of individ-
uals with pre-baseline micro and macroalbuminuria were
reclassified to a less advanced stage of albuminuria at base-
line, and were therefore considered to have regressed.
It has previously been shown that baseline levels of albu-
minuria show a positive correlation with future cardiovascular
events in individuals with diabetes [7–9]. We not only validat-
ed these previous results but we extended them to show that
regression of albuminuria in individuals with type 1 diabetes
is associated with reduced risk for cardiovascular events to the
same level as in those who did not progress in the first place.
Interestingly, similar results have been shown in large clinical
studies such as the Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE) Study [19], which studied
hypertensive individuals with and without diabetes. The
cardiovascular consequences of a 50% reduction in
microalbuminuria has also been studied in individuals with
type 2 diabetes [20], and an adjusted risk of 0.41 after
regression was reported for these individuals. Yet, in a re-
cent paper from DCCT/EDIC [21], remission of albumin-
uria was not found to reduce the cardiovascular risk in
individuals with type 1 diabetes. However, there are pro-
found differences between DCCT/EDIC and the FinnDiane
Study that might explain the contradictory findings. The
DCCT/EDIC represents an intervention study comparing
intensive with conventional insulin therapy (DCCT) with
a subsequent open-label follow-up from the close-out of
the DCCT up to 30 years from baseline (EDIC). The
FinnDiane Study is not an intervention but includes a sub-
stantial number of evenly distributed individuals with type
1 diabetes in Finland. Therefore, our novel observations
regarding the beneficial associations between regression of
albuminuria and the risk for cardiovascular events may be
seen to apply to the type 1 diabetes community in general.
However, the single time point ascertainment of the out-
come in our study is a limitation compared with the regres-
sion assessments based on time-updated measures performed
in the DCCT/EDIC. Indeed, these methodological differences
Table 2 Albuminuria status and age-adjusted risk for cardiovascular events, all-cause mortality rate and cardiovascular mortality rate
Cardiovascular events Mortality rate
Number of
participants
n (%) HR (95% CI) Number of
participants
All-cause Cardiovascular
n (%) HR (95% CI) n (%) HR (95% CI)
Normal AER 2620 166 (6.3) 1 (reference) 2729 137 (5.0) 1 (reference) 64 (2.3) 1 (reference)
Microalbuminuria
Regression 96 10 (10.4) 1.42 (0.75, 2.68) 102 8 (7.8) 1.32 (0.65, 2.69) 4 (3.9) 1.41 (0.51, 3.87)
No change 315 58 (18.4) 2.62 (1.95, 3.54) 336 58 (17.3) 2.87* (2.11, 3.91) 31 (9.2) 3.21 (2.09, 4.93)
Macroalbuminuria
Regression 95 22 (23.2) 3.15 (2.02, 4.92) 111 27 (24.3) 3.86 (2.55, 5.83) 14 (12.6) 4.31 (2.41, 7.68)
No change 323 109 (33.7) 5.49* (4.31, 7.00) 364 140 (38.5) 7.22* (5.69, 9.14) 86 (23.6) 9.90* (7.14, 13.7)
Total 3449 365 (10.6) 3642 370 (10.2) 199 (5.5)
































































Fig. 2 Kaplan–Meier cumulative incidence curves for cardiovascular
events over a follow-up of 15 years stratified by status of albuminuria
at baseline
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could partly explain the contradictory observations made in
these two studies.
Several studies are in agreement with our findings that
albuminuria predicts mortality rate [12–15] and that the risk
of premature death (both cardiovascular and non-
cardiovascular death) increases concomitantly with declining
kidney function [14]. We further extended our findings to
include the impact of regression on mortality rate, and as with
cardiovascular events, regression was associated with a sig-
nificantly lower risk of premature death. The major cause of
death in our cohort was cardiovascular disease and, as expect-
ed, cardiovascular mortality rates were reduced by regression
of albuminuria in the samemanner as all-cause mortality rates.
In contrast to results from the 1980s [1–3], some recent
studies have indicated that microalbuminuria more frequently
reverts to the range of normal AER than remains stable or
progresses to ESRD. Two studies, one in type 1 diabetes [4]
and one in type 2 diabetes [5], that defined regression of
microalbuminuria as a 50% reduction in AER obtained similar
results (58% and 51% 6 year cumulative incidence for regres-
sion, respectively). In the EURODIAB Prospective
Complication Study [6], 50.6% of individuals with type 1
diabetes and microalbuminuria reverted to the normal AER
range over a 7 year follow-up. Also in that study, regression
occurred more frequently than progression, as the observed
progression rate was only 13.9%.
Table 3 Impact of regression of albuminuria on incident cardiovascular events: Cox proportional hazards regression models
History of microalbuminuria, n = 411 History of macroalbuminuria, n = 418 Combined, n = 829
Model 1a 0.51 (0.26, 1.00) 0.60 (0.38, 0.96) 0.57 (0.39, 0.82)
Model 2b 0.50 (0.26, 0.99) 0.59 (0.37, 0.94) 0.57 (0.39, 0.83)
Model 3c 0.55 (0.28, 1.10) 0.95 (0.58, 1.56) 0.74 (0.50, 1.10)
HR (95% CI) are presented for regression of albuminuria (yes/no) at different levels of adjustment separately for participants with a history of
microalbuminuria or macroalbuminuria (sustained and regressed) and for all participants combined
No participants with pre-baseline cardiovascular events were included in the analyses
a Unadjusted regression of albuminuria (yes)
bModel 1 + static covariates (sex, age, age at onset of diabetes)





















































Fig. 3 Kaplan–Meier curves for all-cause mortality rate over a follow-up



















































Fig. 4 Kaplan–Meier curves for cardiovascular mortality rate over a fol-
low-up of 15 years stratified by status of albuminuria at baseline
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Along similar lines, our study also proposes that
microalbuminuria does not always predict inevitable progres-
sion to macroalbuminuria and ESRD. Notably, regression
was more common in the aforementioned studies than our
findings suggest. There may be a few explanations for this
discrepancy. First, we did not have the possibility to examine
changes in AER or ACR as continuous variables and theo-
retically we could therefore have lost valuable information by
looking at only categorical variables. Yet, both Perkins et al
[4] and Araki et al [5] showed surprisingly similar results in
their studies by using categorical traits (regression from
microalbuminuria yes/no; 59% and 54%, respectively) com-
pared with a reduction of 50% in continuous AER measure-
ments. Information on the overlap between the two ap-
proaches was unfortunately not shown. Our findings repre-
sent a snapshot in time not a cumulative incidence, which
also may explain the lower regression rate. We cannot ex-
clude the possibility that undetected regressions may have
occurred between the initial and the revised classifications.
Specifically, the scenario of fluctuating AER levels in the
early stages of diabetic nephropathy, marking a dynamic rath-
er than persistent renal injury, may remain unobserved in our
study setting. In addition, the individuals in the present study
were older, had longer duration of diabetes and higher BP at
baseline compared with the other studies on regression of
albuminuria in type 1 diabetes, which may further contribute
to the differing results.
Another interesting finding of our study is the 23.4% re-
gression from macroalbuminuria, which is strikingly similar
to the regression rate in the microalbuminuric group.
However, keeping in mind that the reference limits represent
artificial cut-off values, this might not be surprising after all
and may be a validation of the results obtained for the indi-
viduals with a history of microalbuminuria. Although the
presence of macroalbuminuria has traditionally been consid-
ered a marker of irreversible renal damage, the concept of
regression from higher levels of albuminuria is not completely
new [22–25].
In clinical studies, intensified interventions (hypertension
and glucose control) have been shown to reduce progression
and even induce regression in both type 1 and type 2 diabetes,
and consequently, varying regression rates have been obtained
[26–30]. Consistent with the findings in the studies by Perkins
et al [4] and the EURODIAB study group [6], we did not find
evidence that renin–angiotensin–aldosterone system (RAAS)
blockade is associated with regression. Regressed vs non-
regressed individuals with a history of macroalbuminuria did
not differ regarding the use of RAAS inhibitors (88% vs
84%), which is no surprise as the majority of individuals at
this stage are designated to antihypertensive medication with
RAAS inhibitors as the first choice. However, the difference
in RAAS inhibitor use between regressed and non-regressed
individuals with a history of microalbuminuria could be
secondary to a more favourable health profile among those
who had returned to normal AER.
A key strength of this study is the large, well-characterised
population. The individuals in the current study represent
nearly 10% of all individuals with type 1 diabetes in Finland
and although the FinnDiane Study is not by definition a
population-based study, the geographical distribution of par-
ticipating individuals largely follows that of the general pop-
ulation. However, as all clinical variables were measured at
the first FinnDiane Study visit, which also was the time point
of the third and final urine sample included in the revised
classification of albuminuria, we could not reliably assess fac-
tors associated with regression in this study. It is possible that
the AERs of a number of regressed individuals levelled to less
advanced stages already before entering the FinnDiane Study,
but as a result of the limitations previously discussed, the exact
time point for this remain unknown. Another disadvantage of
the multicentre study design was the incomplete coverage of
centrally measured AERs, and as a result of which we could
not analyse change in AER/ACR as a continuous variable, as
mentioned before. However, selection bias is less likely in a
nationwide multicentre study compared with single-centre
studies, and as all samples for each participant were analysed
at the same centre, this should have no impact at the individual
level. An additional strength of the study was the high quality
and completeness of register data in addition to follow-up
visits, which resulted in 100% coverage of cardiovascular
events and deaths.
In conclusion, we observed regression in 23% of initially
micro/macroalbuminuric individuals at baseline. A novel
finding was that regression from micro to normoalbuminuria
resulted in a cardiovascular risk and mortality rate no different
from individuals who remained normoalbuminuric, and a sim-
ilar phenomenon was seen for the individuals who regressed
from macroalbuminuria compared with individuals with no
change in microalbuminuria. Our observations underline the
importance of keeping the AER as close to normal levels as
possible in order to improve outcomes in type 1 diabetes.
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